Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Onconova Therapeutics, Inc.)"
Count: 31
Selected: 0
NCT IDTitle
NCT04739293Study of ON 123300 in Patients With Advanced Cancer
NCT02562443Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
NCT02168725Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
NCT02107235Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02075034Three Dosing Schedules of Oral Rigosertib in MDS Patients
NCT02030639Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
NCT01928537Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
NCT01926587Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
NCT01904682Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
NCT01807546Oral Rigosertib for Squamous Cell Carcinoma
NCT01584531Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
NCT01538563Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
NCT01538537Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
NCT01360853Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
NCT01168011Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
NCT01167166Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
NCT01165905Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
NCT01125891Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
NCT01049113Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
NCT01048619Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
NCT00906334Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
NCT00867061Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
NCT00861783Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
NCT00861328Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
NCT00856791Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
NCT00854945Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
NCT00854646Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
NCT04177498Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
NCT02730884Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
NCT04263090Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment